BioCentury | Jul 21, 2014
Emerging Company Profile

Envisia: Ophthalmic nanotechnology

Envisia Therapeutics Inc. is using its PRINT microparticle formulation technology to develop sustained-release, implantable versions of approved drugs for glaucoma and age-related macular edema. The products could solve compliance problems with existing therapeutics and could...
BC Week In Review | Jul 30, 2012
Clinical News

Durezol regulatory update

Novartis disclosed in its 2Q12 earnings that FDA approved an sNDA for Durezol difluprednate treat endogenous anterior uveitis. The topical ophthalmic emulsion containing difluprednate is already marketed to treat inflammation and pain associated with ocular...
BC Week In Review | Jan 30, 2012
Clinical News

Durezol regulatory update

Novartis disclosed in its 4Q11 earnings that it submitted an NDA to FDA for Durezol difluprednate for uveitis. The topical ophthalmic emulsion containing difluprednate is marketed to treat inflammation and pain associated with ocular surgery....
BC Week In Review | Apr 5, 2010
Company News

Alcon, Sirion sales and marketing update

Alcon completed its previously announced acquisition of exclusive, U.S. rights to Durezol difluprednate from Sirion. Alcon also received exclusive, worldwide rights, excluding Latin America, to develop and commercialize Zyclorin cyclosporine. Alcon said it is evaluating...
BC Week In Review | Jan 25, 2010
Company News

Alcon, Sirion sales and marketing update

Alcon also will receive exclusive, worldwide rights, excluding Latin America, to develop and commercialize Zyclorin cyclosporine. The topical ophthalmic immunomodulator and immunosuppressive agent is in preclinical testing for ocular surface diseases, including dry eye. JPMorgan...
BC Extra | Jan 20, 2010
Company News

Alcon to acquire approved ophthalmic drugs

Alcon Inc. (NYSE:ACL) will acquire exclusive, U.S. rights to two approved ophthalmic drugs from Sirion Therapeutics Inc. (Tampa, Fla.): Zirgan ganciclovir ophthalmic gel and Durezol difluprednate. Zirgan was approved in the U.S. in September to...
BioCentury | Sep 7, 2009
Strategy

A rare breed

A rare breed Approval date Company Drug Indication 12/24/08 Ferring Pharmaceuticals A/S Firmagon degarelix acetate Advanced prostate cancer 8/15/08 Prestwick Pharmaceuticals Inc. (A) Xenazine tetrabenazine Chorea of Huntington's disease (HD) 6/23/08 Sirion Therapeutics Inc. Durezol...
BC Week In Review | Mar 23, 2009
Clinical News

Durezol difluprednate regulatory update

FDA accepted for filing an sNDA from Sirion for Durezol difluprednate to treat endogenous anterior uveitis. The PDUFA date is Oct. 24. The topical ophthalmic emulsion containing difluprednate is already approved to treat postoperative ocular...
BC Week In Review | Oct 20, 2008
Clinical News

Durezol difluprednate: Preliminary Phase III data

Preliminary data from a 6-week, double-blind, U.S. Phase III study (ST-601A-001) in 90 patients with endogenous anterior uveitis showed that 4-times-daily Durezol was noninferior to 8-times-daily Pred Forte prednisolone ophthalmic suspension in reducing AC cell...
BC Extra | Oct 15, 2008
Clinical News

Sirion reports Durezol data

Sirion (Tampa, Fla.) said preliminary data showed that four-times-daily Durezol was noninferior to eight-times-daily Pred Forte prednisolone ophthalmic suspension in reducing anterior chamber cell grades, the primary endpoint, at day 14 in the Phase III...
Items per page:
1 - 10 of 33